CoChat

Effect on Body Weight and Safety of RC-1291, a Novel, Orally Available Ghrelin Mimetic and Growth Hormone Secretagogue: Results of a Phase I, Randomized, Placebo-Controlled, Multiple-Dose Study in Healthy Volunteers

Open access
Garcia, Jose M., Polvino, William J. · 2007 · The Oncologist

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Abstract

Purpose.: RC-1291 is a novel, oral ghrelin mimetic and growth hormone (GH) secretagogue being developed to increase appetite and lean muscle mass in patients with cancer-associated anorexia/cachexia. This randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation phase I study in healthy volunteers evaluated RC-1291 once daily (qd) and twice daily (bid) for effect on body weight and safety. Methods.: The study was conducted with three sequential groups of volunteers. Panel A subjects (n = 8) received placebo or RC-1291, 25 mg qd, for 5 days. Panel B subjects received RC-1291, 25 mg bid or 50 mg qd, for 6 days then crossed over to the other dosage for 5 days (n = 12); three subjects received placebo for all 11 doses to maintain double-blinding. Panel C subjects (n = 9) received placebo or RC-1291, 75 mg qd, for 6 days. Results.: Subjects who received RC-1291, 50 or 75 mg, had significant dose-related weight gain after 6 days versus placebo, with the greatest increases seen with daily dosing. The mean increase in weight from baseline after 50 mg qd was 1.25 ± 0.725 kg (p = .0022 versus placebo), and after 75 mg qd it was 1.16 ± 0.651 kg (p = .0022 versus placebo). One subject in the 50 mg qd group had moderate transient elevation in aspartate aminotransferase and alanine aminotransferase levels. No other laboratory or clinical adverse events of consequence were reported. Conclusions.: Results indicate that RC-1291 produces dose-related increases in body weight with no dose-limiting adverse effects, and may be an effective treatment for anorexia/cachexia.

Overview

Integrity signals

Registry

Crossref · 10.1634/theoncologist.12-5-594

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. Kumor, 2006, Biologic activity of RC-1291, a novel oral ghrelin mimetic for the treatment of cancer anorexia/cachexia: Results from a phase I randomized, double-blind, placebo-controlled clinical trial in healthy volunteers, Support Care Cancer, 14, 593

Cited by

See all 129

Metadata

Authors
Garcia, J. M., & Polvino, W. J.
Affiliations
  • a Division of Diabetes, Endocrinology and Metabolism, Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas, USA
  • b Sapphire Therapeutics, Inc., Bridgewater, New Jersey, USA
Venue
The Oncologist
Published
2007-05-01
Volume
12
Issue
5
Pages
594-600
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2166836966
Cited by
129
References
33
Citations by year
2026: 3 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 4 · 2019: 7 · 2018: 4 · 2017: 9 · 2016: 4 · 2015: 8 · 2014: 10 · 2013: 9 · 2012: 14
FWCI
3.67
Type
journal article
Language
en
Open access
Locations
  • The Oncologist (publishedVersion)
  • PubMed (publishedVersion)
Funders
U.S. Food and Drug Administration
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
growth hormone secretagogues, weight gain, dose-dependent effects, drug safety, cachexia, appetite, lean muscle mass, healthy volunteers, dose escalation
MeSH terms
Administration, Oral, Adult, Alanine Transaminase, Analysis of Variance, Aspartate Aminotransferases, Blood Pressure, Body Weight, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Reference Values, Time Factors, Biomarkers, Treatment Outcome, Ghrelin, Receptors, Ghrelin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect on Body Weight and Safety of RC-1291, a Novel, Orally Available Ghrelin Mimetic and Growth Hormone Secretagogue: Results of a Phase I, Randomized, Placebo-Controlled, Multiple-Dose Study in Healthy Volunteers. https://app.cochat.ai/papers/10.1634/theoncologist.12-5-594
The paper
Garcia, J. M., & Polvino, W. J. (2007). Effect on Body Weight and Safety of RC-1291, a Novel, Orally Available Ghrelin Mimetic and Growth Hormone Secretagogue: Results of a Phase I, Randomized, Placebo-Controlled, Multiple-Dose Study in Healthy Volunteers. The Oncologist. https://doi.org/10.1634/theoncologist.12-5-594

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.